AUTHORS
Joseph R Wardell, MPH, Jason Lofters, MB,BS2, Cassandra Chua, MD3, Renee Hodges, BA4, Janna Lipford5, Tarun Aurora, MD, MSCI6, Clifford Takemoto, MD7, Parul Rai, MD8, Bharath Miriyam, MB,BS, MPH9, Jessica Moore, MD10, Nickhill Bhakta11, Robyn Cohen, MD12, Jane Hankins, MD,MS13, Elizabeth Klings, MD14
AFFILIATIONS
1 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
2 Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
3 Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
4 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
5 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
6 Emory University School of Medicine, Atlanta, Georgia, United States
7 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
8 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
9 Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
10 Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
11 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
12 Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
13 Saint Jude Children's Research Hospital, Memphis, Tennessee, United States
14 Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, United States
ABSTRACT
Background: Acute chest syndrome (ACS) is a leading cause of hospitalization and mortality in sickle cell disease (SCD), arising from infection, fat embolism, thrombosis, and/or pulmonary vaso-occlusion. Early identification of patients at risk for moderate/severe ACS could enable timely escalation of care, including simple or exchange red blood cell transfusion. However, severity predictors derive largely from single-center pediatric cohorts, limiting generalizability to adults.
Objective: To determine the associations of prior ACS history and hematologic indices at presentation with ACS severity and assess differences between pediatric and adult populations.
Methods: We retrospectively identified ACS episodes from 2021–2023 at a pediatric center (St. Jude Children's Research Hospital; n=130 patients, 253 episodes) and an adult center (Boston University Chobanian & Avedisian School of Medicine/Boston Medical Center; n=74 patients, 139 episodes). Severity was graded 1–5 using the Sickle Cell Outcome Grading System (SCOGS) (Aurora T., Lancet Haem, 2026). Primary analyses used index episodes; sensitivity analyses included all episodes. The primary outcome was moderate/severe ACS (Grade ≥3: FiO2 ≥50%, BiPAP/high-flow oxygen, or exchange transfusion) at each patient's first ACS episode during the study period ("index" episode). Prior ACS history was a chart-abstracted binary indicator (any documented episode before the index event). With only 20 moderate/severe outcomes among 204 index episodes, primary models used Firth-penalized logistic regression including prior ACS history, hemoglobin, platelet count, and site as a fixed effect (variance components not estimable with 2 sites); hematologic predictors were analyzed as complete cases. Sensitivity analyses modeled ordinal severity across all eligible episodes using cumulative-link mixed models with a patient-level random intercept. Associations are reported as odds ratios (OR) with 95% confidence intervals (CI); an OR <1 indicates lower odds of higher severity, and a CI excluding 1 was considered significant.
Results: The combined cohort was 50% female, had a median age of 24.1 years (18.6 pediatric vs. 32.0 adult; p<0.001), and was predominantly HbSS/HbSβ0 genotype (76.5%). Moderate/severe ACS occurred in 6.9% of pediatric and 14.9% of adult index episodes (Fisher exact p=0.067). Hemoglobin and platelet values were missing for 21% of pediatric vs. 0% of adult episodes. In the primary Firth-penalized model, prior ACS history was associated with 76% lower odds of a moderate/severe index episode (OR, 0.24; 95% CI, 0.09–0.70; p=0.009), persisting in the all-episode sensitivity analysis (OR, 0.20; 95% CI, 0.09–0.44; p<0.001). Hemoglobin at presentation was not associated with severity in the primary index-episode model (OR, 1.05; 95% CI, 0.78–1.40; p=0.74). In sensitivity analysis, each 1 g/dL hemoglobin increase was associated with 30% lower odds of higher severity (OR, 0.70; 95% CI, 0.58–0.85; p<0.001). The association was strongest in adults (OR, 0.64; 95% CI, 0.50–0.81; p<0.001) and was not significant in pediatrics (OR, 0.78; 95% CI, 0.59–1.04; p=0.086). Platelet associations were directionally different in site-specific models. In the pediatric cohort, higher platelet counts (per 100 ×10⁹/L) were associated with increased odds of moderate/severe ACS (OR, 1.09; 95% CI, 1.01–1.29), whereas in the adult cohort they were associated with decreased odds (OR, 0.44; 95% CI, 0.22–0.80).
Conclusion: Prior ACS history was associated with lower-grade subsequent ACS in the combined cohort and may inform risk stratification. However, this finding should not be interpreted as evidence that prior ACS is protective. Patients with a documented ACS history may have received transfusion earlier during the index episode, potentially limiting progression and influencing the observed SCOGS grade. Higher hemoglobin at presentation was associated with lower severity only in the longitudinal all-episode analysis, primarily in adults, suggesting its predictive value at index presentation may be age-dependent and requires further study. The site-specific association between platelets and ACS severity warrants prospective multicenter validation and may clarify differences in ACS pathophysiology across the lifespan, particularly given the differential data completeness observed across sites. Future analyses will examine hydroxyurea as a modifier of clinical and laboratory predictors of subsequent ACS.
DISCLOSURES
Joseph R Wardell, MPH: No relevant conflicts of interest to declare.